Inclusion Criteria:

- Cytological or pathological documented squamous cell carcinoma of oral cavity,
oropharynx, larynx, and hypopharynx; patients with nasopharyngeal carcinoma can be
included if the patients have grades I or II tumors according to the World Health
Organization (WHO) classification

- Stage III or IV according to the American Joint Committee on Cancer (AJCC) Cancer
Staging Manual, Sixth Edition (2002)

- Unresectable or resection with significant morbidity

- Eastern Cooperative Oncology Group (ECOG) performance status 0-2

- Measurable Disease, defined according to Response Evaluation Criteria in Solid Tumors
(RECIST) Criteria

- Bilirubin =< 1.5 x upper limit of normal (ULN)

- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x ULN

- Calculated creatinine clearance >= 55ml/min (using the Cockcroft-Gault formula)

- Platelet count >= 100 x 10^9 /L

- Absolute neutrophil count (ANC) >= 1.25 x 10^9 /L

- Signed informed consent

- Male and female patients with reproductive potential must use an acceptable
contraceptive method

- Authorization from a dentist to begin radiation therapy

Exclusion Criteria:

- Second primary malignancy that is clinically detectable or clinically significant at
the time of consideration for study enrollment

- Inability or unwillingness to comply with radiotherapy

- Evidence of clinically significant congestive heart failure; patients must be able to
tolerate hydration required during cisplatin chemotherapy

- Diarrhea > grade 1 at the time of enrollment

- Prior radiotherapy, chemotherapy, or investigational treatment for squamous cell
carcinoma of head and neck

- Prior treatment with an investigational or marketed inhibitor of the EGFR pathway

- Use of cytochrome P450 3A4 (CYP3A4) inducers

- Presence of systemic metastases (M1)

- Pregnant or breast-feeding women

- Known human immunodeficiency virus (HIV) infection